cgp-56697 and Headache

cgp-56697 has been researched along with Headache* in 1 studies

Trials

1 trial(s) available for cgp-56697 and Headache

Article	Year
Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali. The New England journal of medicine, 2022, Nov-17, Volume: 387, Issue:20 CIS43LS is a monoclonal antibody that was shown to protect against controlled. We conducted a phase 2 trial to assess the safety and efficacy of a single intravenous infusion of CIS43LS against. In Part B, 330 adults underwent randomization; 110 were assigned to each trial group. The risk of moderate headache was 3.3 times as high with 40 mg of CIS43LS per kilogram as with placebo.. CIS43LS was protective against Topics: Adult; Antibodies, Monoclonal, Humanized; Antimalarials; Artemether, Lumefantrine Drug Combination; Headache; Humans; Malaria, Falciparum; Mali; Plasmodium falciparum	2022

Article

Year

Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali.

The New England journal of medicine, 2022, Nov-17, Volume: 387, Issue:20

CIS43LS is a monoclonal antibody that was shown to protect against controlled. We conducted a phase 2 trial to assess the safety and efficacy of a single intravenous infusion of CIS43LS against. In Part B, 330 adults underwent randomization; 110 were assigned to each trial group. The risk of moderate headache was 3.3 times as high with 40 mg of CIS43LS per kilogram as with placebo.. CIS43LS was protective against

Topics: Adult; Antibodies, Monoclonal, Humanized; Antimalarials; Artemether, Lumefantrine Drug Combination; Headache; Humans; Malaria, Falciparum; Mali; Plasmodium falciparum

2022